Please amend the claims as follows:

Cancel claims 1-5

Please add the following new claims 6-14:

6. (New) A crystalline polymorph form I of (-)-4-[4-[4-[4-[4-[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]-methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by formula I

and characterized by the following x-ray powder diffraction pattern presented In Figure 1.

7. (New) A crystalline polymorph form I of(-)-4-[4-[4-[4-[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]-methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by formula I

and characterized by the Infrared spectrum presented In Figure 4.

8. (New) Crystalline polymorph Form I of (-)-4-[4-[4-[4-[4-[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I

and characterized by the following properties:

a Melting Point Range of about 164 to about 165°C1

a specific rotation equal to $[a]^{25}D = -29.4^{\circ 2}$

The X-ray Powder Diffraction Pattern presented In Figure 1;

The Differential Scanning Calorimetry Thermogram presented In Figure 7; and

The Proton NMR Spectrum resented In Figure 10

41449_1.DOC-3-

- 9. (New) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form 1 of claim 6 and a pharmaceutically acceptable carrier.
- 10. (New) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form 1 of claim 7 and a pharmaceutically acceptable carrier.
- 11. (New) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form 1 of claim 8 and a pharmaceutically acceptable carrier.
- 12. (New) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form 1 of claim 6.
- 13. (New) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form 1 of claim 7.
- 14. (New) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form 1 of claim 8.